Ipsen and Blueprint enter exclusive agreement in FOP
We're pleased to share this news from Blueprint Medicines and Ipsen. This news does not change Ipsen’s commitment to developing palovarotene or BLU-782 as potential treatments for FOP. Visit Ipsen's website to read more.
Do you like this post?